Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
GT Biopharma is a pre-revenue clinical-stage biopharmaceutical company focused on immuno-oncology therapeutics, specifically developing natural killer (NK) cell-based therapies and bispecific antibodies for hematologic malignancies and solid tumors. The company's lead programs include GTB-3550 (TriKE platform targeting CD16/IL-15/CD33) and GTB-5550, with clinical development dependent on capital raises given negative operating cash flow and minimal revenue generation. Stock performance reflects extreme volatility typical of binary clinical trial outcomes and financing events.
GT Biopharma operates a typical clinical-stage biotech model: burn cash on R&D to advance drug candidates through FDA trials (Phase I/II/III), then either commercialize independently or out-license to larger pharma partners for upfront payments, development milestones, and royalties. The TriKE platform (tri-specific killer engager) represents differentiated IP in NK cell engagement, but monetization depends entirely on successful clinical readouts demonstrating efficacy and safety. Current burn rate requires continuous equity dilution or partnership deals to fund operations through data catalysts.
Clinical trial data releases (Phase I/II efficacy, safety, response rates for GTB-3550/5550)
FDA regulatory milestones (IND clearances, Fast Track designations, trial design approvals)
Equity financing announcements (dilutive offerings, warrant exercises, reverse splits)
Strategic partnership or licensing deals with larger pharma companies
Competitive clinical data from rival NK cell or bispecific antibody programs
Binary clinical trial risk - single failed Phase II/III readout can render equity worthless, typical of single-asset clinical biotechs without diversified revenue
Regulatory pathway uncertainty for novel NK cell therapies with limited precedent, potentially requiring larger/longer trials than anticipated
Competitive intensity in immuno-oncology with well-funded rivals (Bristol Myers, Fate Therapeutics, Sorrento) developing alternative NK cell platforms
Larger pharma competitors with superior capital resources can accelerate competing programs and dominate KOL relationships
CAR-T and CAR-NK therapies from established players may capture market share before GT Biopharma reaches commercialization
Extreme cash burn with negative $0.0B operating cash flow and 2.70 current ratio suggests imminent need for dilutive financing
ROE of -704.3% and ROA of -210.6% reflect massive equity destruction relative to asset base, indicating high probability of reverse split or bankruptcy without successful trial data
Stock price decline of -78.2% over 12 months severely impairs ability to raise non-dilutive capital, creating death spiral risk
low - Pre-revenue biotechs are largely insulated from GDP cycles as they generate no commercial sales. However, severe recessions can tighten biotech financing markets and reduce M&A activity, impacting ability to raise capital or secure partnerships. Clinical trial timelines proceed independently of economic conditions.
Rising interest rates negatively impact valuation through higher discount rates applied to distant future cash flows (8-15 years out for clinical-stage assets). Higher rates also increase competition for capital as risk-free alternatives become more attractive, compressing biotech valuations and making equity raises more dilutive. Minimal direct impact on operations as company carries no meaningful debt.
Minimal - Company has no debt (Debt/Equity: 0.00) and does not rely on credit markets for operations. Primary capital source is equity financing, making stock price and investor risk appetite the critical funding constraint rather than credit conditions.
Speculative growth - attracts high-risk biotech investors seeking asymmetric returns from binary clinical catalysts. Typical holders include retail momentum traders around data events and specialized healthcare hedge funds with diversified biotech portfolios. Not suitable for value or income investors given pre-revenue status and negative cash flow. Recent -78.2% annual return indicates capitulation by institutional holders.
high - Clinical-stage biotechs exhibit extreme volatility with 50-80% single-day moves common around trial data releases. Micro-cap status ($0.0B market cap) and low liquidity amplify price swings. Beta likely exceeds 2.0x relative to broader market given financing risk and binary event profile.